Problem: Ebola virus; Reaction: fear; Solution: found in 2012 by Fort Detrick & the M-I Complex

Submitted by SteveMT 
-----------------------------------
Nigeria requests US for experimental Ebola drugs
Posted by: APA Posted date : August 6, 2014 at 8:43 pm UTC 13 views In: Africa
http://en.starafrica.com/news/nigeria-requests-us-for-experi...
------------------------------------
The only known effective treatment against Ebola that the government will admit to happens to have been developed by our own friendly and fuzzy military-industrial complex at Fort Detrick and Big Pharma. A solution in search of a problem that has a known public reaction is again occurring. What are the odds?
--------------------------------
http://www.pnas.org/content/109/44/18030.abstract
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques
October 30, 2012 (vol. 109 no. 44)
Gene Garrard Olinger, Jr.
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
James Pettitt
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Do Kim
b)Mapp Biopharmaceutical, Inc., San Diego, CA 92121;
Michael Pauly
bMapp Biopharmaceutical, Inc., San Diego, CA 92121; and
Kevin J. Whaley
bMapp Biopharmaceutical, Inc., San Diego, CA 92121; and
Calli M. Lear
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Julia E. Biggins
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Corinne Scully
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Lisa Hensley
a)Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;
Larry Zeitlin
b)Mapp Biopharmaceutical, Inc., San Diego, CA 92121; and

Abstract

Filovirus infections can cause a severe and often fatal disease in humans and nonhuman primates, including great apes. Here, three anti-Ebola virus mouse/human chimeric mAbs (c13C6, h-13F6, and c6D8) were produced in Chinese hamster ovary and in whole plant (Nicotiana benthamiana) cells. In pilot experiments testing a mixture of the three mAbs (MB-003), we found that MB-003 produced in both manufacturing systems protected rhesus macaques from lethal challenge when administered 1 h postinfection. In a pivotal follow-up experiment, we found significant protection (P < 0.05) when MB-003 treatment began 24 or 48 h postinfection (four of six survived vs. zero of two controls). In all experiments, surviving animals that received MB-003 experienced little to no viremia and had few, if any, of the clinical symptoms observed in the controls. The results represent successful postexposure in vivo efficacy by a mAb mixture and suggest that this immunoprotectant should be further pursued as a postexposure and potential therapeutic for Ebola virus exposure.
http://www.pnas.org/content/109/44/18030.abstract